|
InMed Pharmaceuticals Inc. (INM): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
InMed Pharmaceuticals Inc. (INM) Bundle
In the cutting-edge world of rare cannabinoid pharmaceuticals, InMed Pharmaceuticals Inc. (INM) is pioneering a revolutionary approach to therapeutic development, blending advanced biosynthetic technology with targeted medical solutions. This deep dive into their marketing mix reveals a strategic blueprint that positions the company at the forefront of innovative biopharmaceutical research, targeting critical unmet medical needs in dermatology and ophthalmology while leveraging sophisticated drug delivery platforms that could transform how rare diseases are treated.
InMed Pharmaceuticals Inc. (INM) - Marketing Mix: Product
Biopharmaceutical Product Portfolio
InMed Pharmaceuticals focuses on developing cannabinoid-based pharmaceutical products for rare diseases and specific medical conditions.
| Product Category | Development Stage | Target Indication |
|---|---|---|
| INM-755 (Epidermolysis Bullosa) | Clinical Stage | Dermatological Treatment |
| INM-088 (Glaucoma) | Preclinical Stage | Ophthalmological Treatment |
| INM-405 (Pain Management) | Research Stage | Rare Neurological Conditions |
Technological Platform
InMed utilizes proprietary biosynthetic cannabinoid manufacturing technology.
- Proprietary BioMachine™ biosynthesis platform
- Advanced cannabinoid production methodology
- Precision molecular engineering capabilities
Research Focus Areas
| Research Domain | Primary Therapeutic Target |
|---|---|
| Dermatology | Epidermolysis Bullosa |
| Ophthalmology | Glaucoma |
| Neurological Disorders | Rare Pain Conditions |
Product Development Characteristics
- Rare cannabinoid pharmaceutical development
- Clinical-stage therapeutic candidates
- Innovative drug delivery systems
InMed Pharmaceuticals Inc. (INM) - Marketing Mix: Place
Headquarters and Global Operations
Located at 3131 Arbutus Street, Suite 200, Vancouver, British Columbia, Canada V6J 3N8.
Distribution Channels
| Channel Type | Details |
|---|---|
| Research Institutions | Active collaborations with 3 North American academic research centers |
| Digital Platforms | Virtual clinical trial recruitment platforms |
| Pharmaceutical Networks | Connected with 2 biotechnology research networks |
Geographic Market Focus
- Primary Market: North American pharmaceutical sector
- Secondary Markets: Emerging biotechnology research regions
Strategic Partnerships
Key Research Collaborations:
- University of British Columbia
- University of California research network
- National Institutes of Health partnership program
Clinical Trial Distribution Strategy
| Trial Phase | Geographic Reach | Number of Sites |
|---|---|---|
| Preclinical | North America | 5 research sites |
| Clinical Phase I/II | United States | 3 medical research centers |
InMed Pharmaceuticals Inc. (INM) - Marketing Mix: Promotion
Scientific Conference Presentations Highlighting Research Innovations
InMed Pharmaceuticals participated in the following scientific conferences in 2023-2024:
| Conference Name | Date | Location | Presentation Focus |
|---|---|---|---|
| American Society of Gene & Cell Therapy Conference | May 2023 | Boston, MA | INM-755 cannabinoid therapy research |
| Biotechnology Innovation Organization Conference | June 2023 | San Diego, CA | Cannabinoid manufacturing platform |
Investor Relations Communications
Quarterly financial reporting metrics for 2023:
- Q3 2023 total revenue: $0.24 million
- Research and development expenses: $2.1 million
- Cash and cash equivalents: $6.5 million (as of September 30, 2023)
Digital Marketing Strategy
Digital marketing channels and engagement metrics:
| Platform | Followers/Connections | Average Monthly Engagement |
|---|---|---|
| 4,200 followers | 1,500 post interactions | |
| 2,800 followers | 800 post interactions |
Scientific Publications
Peer-reviewed publications in 2023-2024:
- Journal of Biotechnology: 2 publications
- Molecular Therapy: 1 publication
- Total citations: 37 scientific references
Industry Network Engagement
Biotech and pharmaceutical industry networking metrics:
| Networking Activity | Number of Interactions |
|---|---|
| Industry conferences attended | 4 |
| Strategic partnership discussions | 6 |
| Collaborative research proposals | 3 |
InMed Pharmaceuticals Inc. (INM) - Marketing Mix: Price
Financial Overview
As of Q4 2023, InMed Pharmaceuticals Inc. reported:
- Cash and cash equivalents: $4.1 million
- Total operating expenses: $8.2 million
- Net loss: $7.9 million for the fiscal year
Stock Performance
| Stock Exchange | Ticker Symbol | Trading Price Range (2023-2024) |
|---|---|---|
| NASDAQ | INM | $0.30 - $1.20 per share |
Financing Strategy
Equity Financing Details:
- Common stock issued: 15.3 million shares
- Warrant and option outstanding: 3.7 million
- Funding raised through public offerings: $12.5 million in 2023
Research Funding Sources
| Funding Source | Amount | Purpose |
|---|---|---|
| Equity Financing | $9.3 million | Clinical research development |
| Strategic Partnerships | $2.6 million | Cannabinoid pharmaceutical research |
Market Valuation
Market Capitalization Metrics:
- Market cap range: $15 million - $25 million
- Enterprise value: Approximately $20 million
- Price-to-book ratio: 0.8
Research Stage Pricing Considerations
As a pre-revenue biotechnology company, InMed's pricing strategy is primarily focused on potential future therapeutic market positioning in cannabinoid-based pharmaceutical developments.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.